IVBT (Innovation1 Biotech) Accounts Receivable: $0.00 Mil (As of Feb. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IVBT Innovation1 Biotech Inc IVBT
12 GF Score
Price $0.00
View Full Analysis

What is Innovation1 Biotech Accounts Receivable?

Innovation1 Biotech IVBT 12 Accounts Receivable is $0.00 Mil as of Feb. 2024. GuruFocus rates IVBT with a GF Score™ of 12/100.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Innovation1 Biotech's accounts receivables for the quarter that ended in Feb. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Innovation1 Biotech's Net-Net Working Capital per share for the quarter that ended in Feb. 2024 was $-0.15.

Innovation1 Biotech Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Innovation1 Biotech's Days Sales Outstanding for the quarter that ended in Feb. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Innovation1 Biotech's accounts receivable are only considered to be worth 75% of book value:

Innovation1 Biotech's Net-Net Working Capital Per Share for the quarter that ended in Feb. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.108+0.75 * 0+0.5 * 0-3.459
-0.008-0)/22.470
=-0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Innovation1 Biotech Accounts Receivable Related Terms

Innovation1 Biotech Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Innovation1 Biotech's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation1 Biotech Accounts Receivable Chart

Innovation1 Biotech Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Innovation1 Biotech Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IVBT
12GF Score
Innovation1 Biotech Inc IVBT
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovation1 Biotech Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of $0.00 Mil mean?
Innovation1 Biotech (IVBT) has a Accounts Receivable of $0.00 Mil as of Feb. 2024. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Innovation1 Biotech and its competitors.
Is Innovation1 Biotech's Accounts Receivable too high?
Innovation1 Biotech's current Accounts Receivable is $0.00 Mil. Overall, Innovation1 Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Innovation1 Biotech's Accounts Receivable compare to NVIV and PXMD?
Innovation1 Biotech's Accounts Receivable of $0.00 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Diversified Financial Services company?
A good Accounts Receivable depends on the Diversified Financial Services industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Innovation1 Biotech and its competitors. Innovation1 Biotech's current Accounts Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation1 Biotech stock overvalued right now?
Innovation1 Biotech (IVBT) has a current Accounts Receivable of $0.00 Mil. The current Accounts Receivable is $0.00 Mil. Innovation1 Biotech's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Innovation1 Biotech (IVBT), the current Accounts Receivable is $0.00 Mil as of Feb. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation1 Biotech Business Description

Address 7 Grand View Avenue, Somerville, MA, USA, 02143
Innovation1 Biotech Inc is a shell company.
12GF Score

Get the complete analysis for IVBT

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price